QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:ALBO

Albireo Pharma Competitors

$36.68
-0.10 (-0.27 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.32
Now: $36.68
$37.86
50-Day Range
$34.88
MA: $37.90
$42.85
52-Week Range
$11.26
Now: $36.68
$49.00
Volume97,075 shs
Average Volume182,074 shs
Market Capitalization$699.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Competitors

Albireo Pharma (NASDAQ:ALBO) Vs. XNCR, TARO, AXSM, DCPH, CYRX, and LGND

Should you be buying ALBO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Albireo Pharma, including Xencor (XNCR), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Deciphera Pharmaceuticals (DCPH), Cryoport (CYRX), and Ligand Pharmaceuticals (LGND).

Albireo Pharma (NASDAQ:ALBO) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Institutional and Insider Ownership

85.7% of Albireo Pharma shares are held by institutional investors. 5.0% of Albireo Pharma shares are held by insiders. Comparatively, 3.7% of Xencor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Albireo Pharma and Xencor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Albireo Pharma$9.64 million72.59$-62,720,000.00($5.04)-7.28
Xencor$156.70 million17.78$26.88 million$0.46105.43

Xencor has higher revenue and earnings than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Albireo Pharma and Xencor, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Albireo Pharma00803.00
Xencor20802.60

Albireo Pharma presently has a consensus price target of $69.4286, indicating a potential upside of 89.28%. Xencor has a consensus price target of $46.70, indicating a potential downside of 3.71%. Given Albireo Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Albireo Pharma is more favorable than Xencor.

Profitability

This table compares Albireo Pharma and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Albireo Pharma-751.53%-71.22%-42.91%
Xencor-113.40%-13.56%-12.03%

Risk and Volatility

Albireo Pharma has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Summary

Albireo Pharma beats Xencor on 7 of the 13 factors compared between the two stocks.

Taro Pharmaceutical Industries (NYSE:TARO) and Albireo Pharma (NASDAQ:ALBO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Taro Pharmaceutical Industries and Albireo Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taro Pharmaceutical Industries00103.00
Albireo Pharma00803.00

Taro Pharmaceutical Industries presently has a consensus target price of $81.00, suggesting a potential upside of 11.29%. Albireo Pharma has a consensus target price of $69.4286, suggesting a potential upside of 89.28%. Given Albireo Pharma's higher probable upside, analysts plainly believe Albireo Pharma is more favorable than Taro Pharmaceutical Industries.

Profitability

This table compares Taro Pharmaceutical Industries and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taro Pharmaceutical Industries-45.94%10.36%8.38%
Albireo Pharma-751.53%-71.22%-42.91%

Risk and Volatility

Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation and Earnings

This table compares Taro Pharmaceutical Industries and Albireo Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taro Pharmaceutical Industries$644.77 million4.32$244.24 million$6.3511.46
Albireo Pharma$9.64 million72.59$-62,720,000.00($5.04)-7.28

Taro Pharmaceutical Industries has higher revenue and earnings than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are owned by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Comparatively, 5.0% of Albireo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Taro Pharmaceutical Industries beats Albireo Pharma on 7 of the 13 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and Albireo Pharma (NASDAQ:ALBO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Risk and Volatility

Axsome Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Axsome Therapeutics and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Albireo Pharma-751.53%-71.22%-42.91%

Valuation and Earnings

This table compares Axsome Therapeutics and Albireo Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-35.81
Albireo Pharma$9.64 million72.59$-62,720,000.00($5.04)-7.28

Albireo Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Axsome Therapeutics and Albireo Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Albireo Pharma00803.00

Axsome Therapeutics presently has a consensus price target of $146.80, suggesting a potential upside of 103.95%. Albireo Pharma has a consensus price target of $69.4286, suggesting a potential upside of 89.28%. Given Axsome Therapeutics' higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Albireo Pharma.

Summary

Axsome Therapeutics beats Albireo Pharma on 7 of the 13 factors compared between the two stocks.

Albireo Pharma (NASDAQ:ALBO) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Albireo Pharma and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Albireo Pharma-751.53%-71.22%-42.91%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Analyst Recommendations

This is a summary of recent recommendations for Albireo Pharma and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Albireo Pharma00803.00
Deciphera Pharmaceuticals03602.67

Albireo Pharma presently has a consensus target price of $69.4286, indicating a potential upside of 89.28%. Deciphera Pharmaceuticals has a consensus target price of $69.4444, indicating a potential upside of 60.60%. Given Albireo Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Albireo Pharma is more favorable than Deciphera Pharmaceuticals.

Risk & Volatility

Albireo Pharma has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Institutional & Insider Ownership

85.7% of Albireo Pharma shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by company insiders. Comparatively, 7.0% of Deciphera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Albireo Pharma and Deciphera Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Albireo Pharma$9.64 million72.59$-62,720,000.00($5.04)-7.28
Deciphera Pharmaceuticals$25 million99.67$-192,260,000.00($4.48)-9.65

Albireo Pharma has higher earnings, but lower revenue than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks.

Cryoport (NASDAQ:CYRX) and Albireo Pharma (NASDAQ:ALBO) are both transportation companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Cryoport and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
Albireo Pharma-751.53%-71.22%-42.91%

Risk and Volatility

Cryoport has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Institutional and Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 5.0% of Albireo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Cryoport and Albireo Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million71.38$-18,330,000.00($0.55)-111.05
Albireo Pharma$9.64 million72.59$-62,720,000.00($5.04)-7.28

Cryoport has higher revenue and earnings than Albireo Pharma. Cryoport is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Cryoport and Albireo Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
Albireo Pharma00803.00

Cryoport presently has a consensus price target of $52.4286, indicating a potential downside of 14.16%. Albireo Pharma has a consensus price target of $69.4286, indicating a potential upside of 89.28%. Given Albireo Pharma's higher probable upside, analysts clearly believe Albireo Pharma is more favorable than Cryoport.

Summary

Cryoport beats Albireo Pharma on 8 of the 13 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Albireo Pharma (NASDAQ:ALBO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

85.7% of Albireo Pharma shares are held by institutional investors. 10.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ligand Pharmaceuticals and Albireo Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals03502.63
Albireo Pharma00803.00

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 47.33%. Albireo Pharma has a consensus price target of $69.4286, indicating a potential upside of 89.28%. Given Albireo Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Albireo Pharma is more favorable than Ligand Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Albireo Pharma-751.53%-71.22%-42.91%

Earnings & Valuation

This table compares Ligand Pharmaceuticals and Albireo Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million19.57$629.30 million$2.1169.36
Albireo Pharma$9.64 million72.59$-62,720,000.00($5.04)-7.28

Ligand Pharmaceuticals has higher revenue and earnings than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ligand Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.


Albireo Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xencor logo
XNCR
Xencor
1.0$48.50-0.3%$2.79 billion$156.70 million-34.64Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.78-0.6%$2.78 billion$644.77 million-10.38News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$71.98-2.8%$2.69 billionN/A-26.76Upcoming Earnings
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.24-1.4%$2.49 billion$25 million-8.65
Cryoport logo
CYRX
Cryoport
1.3$61.08-1.6%$2.42 billion$33.94 million-105.31
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.34-3.5%$2.35 billion$120.28 million-147.82
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$35.33-5.8%$2.29 billion$15 million-18.50News Coverage
Endo International logo
ENDP
Endo International
1.4$9.87-0.6%$2.27 billion$2.91 billion-14.51Upcoming Earnings
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$61.85-4.4%$2.16 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Analyst Revision
Gap Up
HRMY
Harmony Biosciences
1.3$37.15-0.7%$2.11 billionN/A0.00Upcoming Earnings
News Coverage
GBIO
Generation Bio
1.3$37.81-8.8%$2.11 billionN/A0.00Upcoming Earnings
Analyst Report
Gap Down
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.6$28.02-3.0%$2.10 billion$23.90 million-17.40Upcoming Earnings
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.07-1.4%$2.10 billion$963.01 million13.07
STOK
Stoke Therapeutics
1.4$60.62-2.2%$2.03 billionN/A-33.68Insider Selling
News Coverage
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$22.27-1.1%$2.02 billionN/A-7.93
ADCT
ADC Therapeutics
1.6$28.59-2.4%$1.97 billion$2.34 million-12.11Upcoming Earnings
NGM
NGM Biopharmaceuticals
1.7$28.50-1.0%$1.97 billion$103.54 million-21.43
PRAX
Praxis Precision Medicines
1.6$50.56-4.0%$1.93 billionN/A0.00
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$122.80-2.1%$1.90 billionN/A-11.09
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.58-1.4%$1.86 billion$320,000.00-9.92News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$40.30-1.9%$1.85 billion$29.54 million-10.69Upcoming Earnings
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.80-6.3%$1.81 billion$34.51 million-16.92Upcoming Earnings
News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$50.11-2.6%$1.80 billionN/A0.00
ImmunoGen logo
IMGN
ImmunoGen
1.3$9.13-0.4%$1.78 billion$82.27 million-22.27
FREQ
Frequency Therapeutics
1.3$52.38-7.4%$1.77 billion$28.95 million-74.83News Coverage
Gap Down
PMVP
PMV Pharmaceuticals
1.2$39.20-6.2%$1.76 billionN/A0.00Upcoming Earnings
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$19.31-7.5%$1.75 billion$145.97 million-7.82Upcoming Earnings
News Coverage
ARQT
Arcutis Biotherapeutics
1.6$35.00-2.4%$1.75 billionN/A-3.79Analyst Downgrade
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$26.17-1.0%$1.74 billion$410,000.00-5.69Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
NKTX
Nkarta
1.6$51.58-4.5%$1.68 billionN/A0.00Upcoming Earnings
ATBPD
Antibe Therapeutics
0.1$4.32-6.2%$1.67 billion$7.51 million-7.20High Trading Volume
Gap Down
STTK
Shattuck Labs
1.3$40.02-5.0%$1.67 billionN/A0.00Upcoming Earnings
News Coverage
uniQure logo
QURE
uniQure
1.9$37.47-3.4%$1.67 billion$7.28 million-9.94Upcoming Earnings
Unusual Options Activity
OLMA
Olema Pharmaceuticals
1.7$43.18-1.5%$1.66 billionN/A0.00News Coverage
Kura Oncology logo
KURA
Kura Oncology
1.6$29.15-14.3%$1.65 billionN/A-17.88Analyst Report
News Coverage
Gap Down
KRON
Kronos Bio
1.8$29.23-1.8%$1.64 billionN/A0.00
ZNTL
Zentalis Pharmaceuticals
1.8$40.26-10.3%$1.64 billionN/A0.00Upcoming Earnings
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$30.94-4.4%$1.63 billion$392.76 million12.84Upcoming Earnings
News Coverage
ORGO
Organogenesis
1.0$14.59-8.6%$1.57 billion$260.98 million-243.17
TVTX
Travere Therapeutics
1.4$29.95-1.0%$1.53 billion$175.34 million-17.62Upcoming Earnings
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.10-5.9%$1.53 billion$1.63 billion12.44Upcoming Earnings
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.30-1.9%$1.49 billion$428.41 million13.48Earnings Announcement
Analyst Downgrade
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$21.87-0.1%$1.49 billionN/A-9.23Earnings Announcement
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$36.50-4.2%$1.48 billionN/A-12.29Upcoming Earnings
Analyst Upgrade
High Trading Volume
Cytokinetics logo
CYTK
Cytokinetics
1.7$20.75-2.4%$1.47 billion$26.87 million-10.86Upcoming Earnings
PLRX
Pliant Therapeutics
1.5$40.06-14.8%$1.42 billion$57.05 million0.00Upcoming Earnings
News Coverage
MannKind logo
MNKD
MannKind
1.0$5.98-11.7%$1.39 billion$63.04 million-28.47Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$56.98-3.6%$1.39 billionN/A-16.91Analyst Revision
Omeros logo
OMER
Omeros
1.0$22.49-1.5%$1.39 billion$111.81 million-9.45Upcoming Earnings
Insider Selling
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.75-0.8%$1.38 billion$6.20 million-13.93
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.